Ian D. Davis, MBBS, PhD | Authors

Ian D. Davis, MBBS, PhD, Reviews Interesting Data From TheraP Trial of 177Lu-PSMA-617 in mCRPC at 2022 ASCO

August 29, 2022

Ian D. Davis, MBBS, PhD, spoke about the TheraP study which evaluated 177Lu-PSMA-617 vs cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Ian D. Davis, MBBS, PhD, Dives Into Subgroup Data from the ENZAMET Trial of Enzalutamide in mHSPC at 2022 ASCO

August 13, 2022

Ian D. Davis, MBBS, PhD, spoke about the subgroup analysis of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.

Ian D. Davis, MBBS, PhD, Details Rationale and Topline Survival Results of the ENZAMET Trial Examining Enzalutamide in mHSPC at 2022 ASCO

August 01, 2022

Ian D. Davis, MBBS, PhD, spoke about updated survival results of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.